Please login to the form below
Seattle Genetics
This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
AZ nabs US approval for new leukaemia drug Lumoxiti
Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
Latest news
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
to license it to Seattle Genetics last year - while other breast cancer ADCs on the agenda at ASCO include Daiichi is developing trastuzumab deruxtecan and Takeda/Mersana’s XMT-1522.
-
Seattle Genetics claims key US approval for Adcetris
Seattle Genetics claims key US approval for Adcetris. Becomes the first new treatment for advanced Hl in more than 40 years. ... Seattle Genetics has won FDA approval for Adcetris as a first-line treatment for advanced Hodgkin’s lymphoma, which it
-
Takeda bags EU approval for Adcetris in lymphoma
Originally developed by Seattle Genetics, Adcetris has been on the market for just over six years and has seen sales grow steadily to around $600m last year, driven by a stream ... There are more new indications on the way, and Takeda and Seattle
-
Seattle Genetics' Adcetris earns FDA priority review status
Seattle Genetics' Adcetris earns FDA priority review status. The win follows a breakthrough designation from the US regulator last year. ... Seattle Genetics’Adcetris has received a boost after the US Food and Drug Administration’s (FDA) granted the
-
Astellas extends phase III programme for Rydapt rival gilteritinib
It also has a 10-year-plus collaboration with Seattle Genetics covering microtubule-disrupting antibody-drug conjugates.
More from news
Approximately 6 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Undeterred Seattle Genetics went on to buy Cascadian Therapeutics at the very end of January for
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals in June 2015
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints CCO, Stephen Davies joins Eisai and more
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
-
Douglas Williams named president and CEO of Codiak
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
-
VentiRx appoints James Kyle Bryan as chief medical officer
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Associate Medical Director
-
Highly Competitive
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Associate Director
-
£75, 000-90, 000
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Competitive Salary
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Medical Writers
-
Competitive Salary and Benefits
-
New Business Director - PR
-
Competitive Salary and benefits
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical/ Scientific Director
-
Salary TBC
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
Subscribe to our email news alerts
- Key considerations for disease- modifying Parkinson’s disease trials
- Artificial Intelligence In Healthcare Market to Witness Exponential Growth by 2027
- Breathing Exercise Devices Market Intelligence Report Offers Growth Prospects
- Micro-CT Scanners Market 10-Year Market Forecast and Trends Analysis Research Report
- Next Generation Infusion Pump Market Healthy Pace throughout the Forecast during 2017 – 2027
- Wireless Brain Sensors Market Intelligence Report Offers Growth Prospects
PMHub
Nobull Communications
Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
